Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT01769378

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01769378
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Croatia, Mexico, Romania, Slovenia, South Africa (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01769378. Randomized; triple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2015-10-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
Acronym
AWARD-8
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Placebo
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Glimepiride
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01769378
Content hash
1709b49cee292f07013e35a84e76f54380077daaa2bff2a11e91e6d16e8b0fd2